Investors with substantial losses from investments in ViroPharma, Inc. (VPHM) as a result of ViroPharma’s unfair methods of competition are encouraged to contact the Leading Investment Losses Law Firm of Gilman Law LLP to discuss your rights.

The Leading Investment Losses and Stock Fraud Law Firm of Gilman Law LLP is investigating potential claims on behalf of purchasers of ViroPharma Inc. (“ViroPharma” or the “Company”) (NASDAQ:VPHM) common stock concerning possible violations of federal securities laws.

Information about the ViroPharma Class Action Securities Lawsuit

ViroPharma Class Action Securities Lawsuit

The Federal Trade Commission is currently investigating whether ViroPharma engaged in unfair methods of competition in relation to its antibiotic Vancocin. Furthermore, the Food and Drug Administration recently denied ViroPharma’s petition to maintain market exclusivity. By April 11, 2012, four companies began selling authorized generic versions of Vancocin. Since announcing the investigation by the Federal Trade Commission, shares of ViroPharma have fallen over 21 percent.

If you own or otherwise acquired ViroPharma stock and wish to obtain additional information about the investigation and your legal rights, please contact our experienced securities attorneys via email at consultations@gilmanlawllp.com, by telephone toll free at (888) 252-0048, or by completing the free online legal consultation form to the left of this page.

About Gilman Law LLP

The experienced Investment Losses and Securities Law Attorneys at Gilman Law LLP have over 35 years of experience in complex securities litigation involving securities fraud, derivative claims, and other shareholder lawsuits. The securities attorneys at Gilman Law LLP have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered hundreds of millions of dollars on behalf of investors.